Business Wire

Orca Bio Announces the Precision-T Phase 3 Study is Open and Enrolling Patients at Transplant Centers Across the U.S.

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer, genetic blood disorders and autoimmune diseases, ...
MedCity News

Precision Bio Offloads Lead Cell Therapy Program in Pivot to In Vivo Gene Editing

Precision BioSciences’ most advanced cell therapy for a type of blood cancer is on track for a pivotal clinical trial, but that study is no longer its responsibility. The biotech is outlicensing ...
MedCity News

Novartis picks Precision Bio to bring in vivo gene editing meds to blood disorders

Genetic medicines in development for blood disorders include several therapies made by taking a patient’s cells and editing them outside of the body. Novartis is one of the companies testing this ...
Seeking Alpha

Precision Bio gains on early Phase 1 data for Hep B candidate

Precision BioSciences (NASDAQ:DTIL) added ~6% in the premarket on Wednesday after the gene therapy developer announced initial safety and efficacy data from an early-stage trial for its Hepatitis B ...
Seeking Alpha

Precision Bio rises after gene editing data: BMO upgrades (update)

Precision BioSciences (NASDAQ:DTIL) added ~26% in the morning hours on Friday after the gene-editing company said ECUR-506, one of its lead candidates, generated a complete clinical response in a ...
Business Wire

Precision Cancer Consortium Teams Up with Massive Bio to Utilize AI Analytics and Enhance Clinical Trial Matching for Cancer Patients Worldwide

NEW YORK--(BUSINESS WIRE)--Massive Bio, a leading artificial intelligence (AI) analytics company specializing in precision oncology, has been selected by the Precision Cancer Consortium (PCC), a ...